Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TC-110 T Cells · 1 trial · 6 indications
| Arm | Type | Description |
|---|---|---|
| Phase 1 | EXPERIMENTAL | The Phase 1 portion of the study will proceed according to a standard 3 + 3 dose escalation schema. Patients will be enrolled into 3 cohorts based on disease: NHL cohort, low tumor burden ALL cohort, and high tumor burden ALL cohort. |
| Phase 2 | EXPERIMENTAL | The phase 2 portion of the study will evaluate the efficacy of TC-110 T cells administered at the RP2D, preceded by a lymphodepleting regimen. |
| Name | Type | Description |
|---|---|---|
| TC-110 T Cells | DRUG | TC-110 T Cells |
| Fludarabine | DRUG | Flu/Cy Lymphodepletion |
| Cyclophosphamide | DRUG | Flu/Cy Lymphodepletion |
Inclusion Criteria: * Patient is \> 18 years of age at the time the Informed Consent is signed * Patient has agreed to abide by all protocol-required procedures, including study-related assessments, and management by the treating institution for the duration of the study and LTFU * Histologically c...
TC-110 T Cells is an investigational cell therapy being developed by Adaptimmune Therapeutics PLC for non-Hodgkin lymphoma. It has been studied in adults with relapsed or refractory non-Hodgkin lymphoma or acute lymphoblastic leukemia, including diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma, mantle cell lymphoma, and follicular lymphoma.
TC-110 T Cells is being studied for relapsed or refractory non-Hodgkin lymphoma in adults. The clinical program also enrolled patients with acute lymphoblastic leukemia and several lymphoma subtypes, including diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma, mantle cell lymphoma, and follicular lymphoma.
TC-110 T Cells is being developed by Adaptimmune Therapeutics PLC, which trades under the ticker ADAPY. The company is the sponsor of the clinical program evaluating the therapy in relapsed or refractory non-Hodgkin lymphoma and acute lymphoblastic leukemia.
TC-110 T Cells is in Phase 1/2 clinical development. It is an investigational therapy and is not described as FDA approved. The Phase 1/2 study evaluating it has been completed, and no trials of TC-110 T Cells are currently listed as active.
TC-110 T Cells has been evaluated in one clinical trial, NCT04323657, titled TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia. The Phase 1/2 study was completed, enrolled 6 patients, was conducted in the United States, and included adults 18 years and older.